ERBB2 and PTPN2 gene copy numbers as prognostic factors in HER2-positive metastatic breast cancer treated with trastuzumab

Trastuzumab has markedly improved the treatment and long-term prognosis of patients with HER2-positive breast cancer. A frequent clinical challenge in patients with relapsing and/or metastatic disease is de novo or acquired trastuzumab resistance, and to date no predictive biomarkers for palliative...

Descripción completa

Detalles Bibliográficos
Autores principales: Ellegård, Sander, Veenstra, Cynthia, Pérez-Tenorio, Gizeh, Fagerström, Victor, Gårsjö, Jon, Gert, Krista, Sundquist, Marie, Malmström, Annika, Wingren, Sten, Elander, Nils O., Hallbeck, Anna-Lotta, Stål, Olle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2019
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6396168/
https://www.ncbi.nlm.nih.gov/pubmed/30867772
http://dx.doi.org/10.3892/ol.2019.9998

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6396168/
https://www.ncbi.nlm.nih.gov/pubmed/30867772
http://dx.doi.org/10.3892/ol.2019.9998

Ejemplares similares